top of page
  • Writer's pictureRichard Kadri-Langford

Celebrating a Milestone in Oculomics: Our Latest Publication in the Journal of Ophthalmology and Therapy

We are delighted to announce the publication of a significant new review article, "Oculomics: A Crusade Against the Four Horsemen of Chronic Disease," in the prestigious Journal of Ophthalmology and Therapy. This article represents a significant achievement for the team at Occuity, underpinned by the dedication and extensive effort of Dr Emily J. Patterson, with contributions from Dr Alistair D. Bounds, Richard Kadri-Langford, Dr Robin Taylor, and Dr Dan Daly.


A special note of thanks is due to Dr Siegfried K. Wagner for his support and significant contributions to the research, which will help to propel scientific and clinical awareness of the burgeoning field of Oculomics forward.


The Journal of Ophthalmology and Therapy, part of the respected Springer publishing group, is known for its rigorous peer-review process and dedication to advancing knowledge in the field of ophthalmology. Publishing in this journal underscores the innovative and high-quality research conducted by all the contributors. More about the journal can be found here: Springer - Journal of Ophthalmology and Therapy.


The article itself delves into the emerging field of Oculomics, which explores the potential of ocular biomarkers in diagnosing and monitoring chronic diseases—termed as the 'Four Horsemen' of chronic disease: cardiovascular disease, cancer, neurodegenerative, and metabolic diseases which kill around 80% of the population. The article assesses the current state-of-the-art around how the eye, as an accessible window to systemic health, can reveal critical insights into these conditions, marking a significant stride towards non-invasive diagnostics.

This publication not only solidifies Occuity's position as a leader in the field of Oculomics but also opens new avenues for non-invasive diagnostic solutions that could transform patient care across multiple disease states.


We invite you to read the full open-access article here and welcome any inquiries, discussions, or potential collaborations that can further enhance our research and applications in Oculomics. Please contact us if you're interested in learning more or discussing future projects.

58 views0 comments


bottom of page